Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors

Published November 30, 2016 | Version v1

Journal article Open

1. Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts
2. Department of Medicine, Stanford University Medical School, Stanford, California3Deputy Editor, JAMA Cardiology
3. Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
4. The Medicines Company, Parsippany, New Jersey
5. French Alliance for Cardiovascular Clinical Trials, Départements Hospitalo-Universitaires Fibrosis, Inflammation, Remodeling, Institut National de la Santé et de la Recherche Médicale, Paris, France7Hôpital Bichat, Assistance-Publique–Hôpitaux de Paris, Paris, France8National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, England
6. Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
7. Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany
8. Scripps Clinic and Scripps Translational Science Institute, La Jolla, California
9. Azienda Ospedaliero-Universitaria di Parma, Province of Parma, Italy
10. Department of Medicine, Stanford University Medical School, Stanford, California
11. Green Lane Cardiovascular Service, Auckland, New Zealand

n/a

Files

Name	Size	Download all
fulltext.pdf md5:cfca616f348f67b2353a5e3ea156b3db	186.3 kB	Preview Download